Optimize your pharmaceutical portfolio strategy

Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
Country-specific treatment algorithms and reimbursement scenarios
Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

COVID-19 Pandemic Accelerates Shift Toward Virtual Trials

06 May 2020

As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.

Datamonitor Healthcare Podcast 05 January 2018

07 Jan 2018

Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast. This episode of the podcast features a roundtable discussion of potential deals prior to the JPM Healthcare Conference.

Depression drug market

23 Sep 2017

Deep Dive : Depression Drug Development

Inside the payer perspective market

08 Jun 2017

Market Access & Reimbursement: Inside the Payer Perspective on Multiple Myeloma

Datamonitor Healthcare

Disappointing Translarna failure is an isolated event for CF pipeline

30 Mar 2017

PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.

AHA 2016: Type 2 diabetes treatment is shifting towards therapies with cardiovascular benefits

22 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.

AHA 2016: Significant increase in SGLT-2 inhibitor use expected in type 2 diabetes

15 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans expect recent CVOT data to lead to increased use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, despite uncertainty surrounding the mechanism of the drugs’ observed cardiovascular (CV) benefit.

Datamonitor Healthcare

Ensure your successful entrance into the Hepatitis B market

01 Jul 2016

Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.

Gilead to tread gently with Sovaldi’s pricing in China

25 Aug 2015

Gilead is negotiating Sovaldi’s (sofosbuvir) pricing with the Chinese government. This is a necessary step to ensure the company captures China’s large hepatitis C population, following its decision to exclude the country from its drug access program, and to also avoid the potential negative repercussions in other emerging markets should China resort to compulsory licensing.

Datamonitor Healthcare

Discovering colorectal cancers market dynamics

03 Mar 2015

Did you know the colorectal cancer market value will increase from $7bn to $7.6bn in the forecast period? With our infographic you'll be able to look through all of the key highlights of our colorectal cancer forecast report.

Datamonitor Healthcare